Mode
Text Size
Log in / Sign up
N/A N=213 Randomized Single-blind Treatment

Cognitive Training for Nicotine Dependence

Tobacco Use Disorder · Nicotine Addiction

Enrolled (actual)
213
Serious AEs
4.2%
Results posted
Jan 2017
Primary outcome: Primary: Point-prevalence Abstinence at End of Treatment — 38; 43 Percentage of participants — p=0.14

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Cognitive Training (Behavioral); Control training (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Pennsylvania
Primary completion
Sep 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Point-prevalence Abstinence at End of Treatment
38; 43 0.14
SECONDARY
Point-prevalence Abstinence at 6-month Follow-up
15; 25
SECONDARY
Cognitive Performance (Working Memory)
0.22; 0.03 0.30
SECONDARY
Cognitive Performance (Response Inhibition)
-0.84; -0.49 0.30
SECONDARY
Cognitive Performance (Attention)
-0.27; 0.54 0.033 sig

Summary

This randomized clinical trial tested the effects of a computerized (web-based) cognitive training intervention on smoking cessation. All participants received 8 weeks of standard nicotine patch therapy, smoking cessation counseling, and were randomized to 1 of 2 different training programs: cognitive training vs. control training.

Eligibility Criteria

Inclusion:

  • Healthy male and female treatment-seeking smokers who are between 18 and 65 years of age and self-report smoking at least 5 cigarettes (menthol and/or non-menthol) per day for at least the last 6 months
  • Plan to live in the area for at least the next 8 months
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the combined consent and HIPAA form
  • Able to communicate fluently in English (speaking, writing, and reading)
  • Have uninterrupted access to a home computer with sound capabilities, keyboard, mouse, and active Internet connection
  • Provide a Carbon Monoxide (CO) breath test reading greater than or equal to 8 parts per million (ppm) at Intake Visit
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01252966). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search